Open AccessPneumonitis as a complication of immune system targeting drugs?—a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials
Author(s) -
Mohamed Rahouma,
Massimo Baudo,
Maha Yahia,
Mohamed Kamel,
Katherine D. Gray,
Adham Elmously,
Galal Ghaly,
Ihab Eldessouki,
Ahmed Abouarab,
Ali N. Cheriat,
N. Abdel Karim,
Abdelrahman Mohamed,
John C. Morris,
Mario Gaudino
Publication year - 2019
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2019.01.19
Subject(s) - medicine , pneumonitis , nivolumab , immunotherapy , randomized controlled trial , pembrolizumab , oncology , clinical endpoint , lung cancer , clinical trial , radiation therapy , cancer , surgery , lung
Anti-PD/PD-L1-targeted immunotherapy is associated with remarkably high rates of durable clinical responses in patients across a range of tumor types, although their high incidence of skin, gastrointestinal, and endocrine side effects with their use. The risk of pneumonitis associated with checkpoint inhibition therapy is not well described.